Repligen (RGEN) Q3 2024 earnings summary

Executive summary

• Q3 2024 revenue reached $155 million, up 10% year-over-year, driven by strong CDMO and new modalities performance, and robust order intake outpacing sales by 4%.

• CDMO business rebounded to its highest revenue in 18 months, with new modalities delivering record quarterly revenue, tracking to 20% of total revenue for the year.

• Americas and Asia (ex-China) showed robust growth, while China remained a significant headwind, representing only about 4% of 2024 revenues.

• Net loss for Q3 2024 was $0.7 million, primarily due to higher SG&A expenses and stock compensation from the CEO transition.

• Announced pending acquisition of Tantti Laboratory Inc. and opened the Repligen Training and Innovation Center.

Financial highlights

• Q3 2024 revenue was $155 million, up 10% year-over-year and 7% organically; recent acquisitions contributed 3% to growth.

• Adjusted gross profit was $78 million, up $19 million year-over-year, with adjusted gross margin at 50.7%, up 8.7 percentage points.

• Adjusted income from operations was $23 million, up $18 million year-over-year; adjusted EBITDA margin was approximately 21%.

• Adjusted net income for Q3 was $24 million, with adjusted diluted EPS of $0.43, compared to $0.23 in Q3 2023.

• Cash position at quarter-end was $784 million, up from $751 million at year-end 2023.

Outlook and guidance

• Full-year 2024 revenue guidance narrowed to $630–$639 million, including $7 million incremental revenue from a restatement.

• Adjusted gross margin guidance raised to 49.5%-50.5%; adjusted operating income expected at $80–$85 million (12.5%-13.5% margin).

• Adjusted EBITDA margin expected at 17.5%-18.5%; adjusted net income guidance is $85–$89 million, with adjusted EPS of $1.50–$1.58.

• Management expects operating expenses to increase as the company expands its bioprocessing business and invests in new product lines.

• 2025 expected to see continued margin expansion and normalization of seasonality, with growth drivers in ATF, systems, and new modalities.